The exercise of warrants for $4.4 million in gross proceeds directly impacts Avenue Therapeutics by increasing its cash reserves. This influx of funds is likely to be viewed positively by investors as it enhances the company's financial stability and provides more flexibility for future operations, investments, and potential growth opportunities. The direct mention of ATXI and the specific financial figure involved allows for a high degree of confidence in the analysis.